ArticleImmunoTargets and therapy2025
A Critical Role of DC-SIGN
Article in ImmunoTargets and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- Transmembrane lectins in cancer immunity: emerging drivers of myeloid-mediated immunosuppression.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Tumor-associated macrophages (TAMs) play a pivotal role in facilitating tumor immune escape in colorectal cancer (CRC). C-type lectin Dendritic Cell-Specific ICAM-Grabbing Nonintegrin (DC-SIGN) is variably expressed in TAMs in tumor tissues. However, its role in CRC progression remains poorly defined. Methods: We analyzed The Cancer Genome Atlas (TCGA) data and an independent CRC cohort to evaluate the prognostic significance of DC-SIGN Results: DC-SIGN was specifically expressed in TAMs within CRC tissues and was associated with increased stromal and immune cell infiltration. DC-SIGN expression correlated with worsened prognosis in CD8 Conclusion: The DC-SIGN/BCL-3 axis in TAMs drives PD-L1 expression and contributes to CRC immune evasion. Targeting DC-SIGN
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.